We are open with limited hours and staff.
Price range: $166.00 through $1,086.00
Methylphenidate hydrochloride 18mg extended-release is a prescription central nervous system stimulant used as part of a comprehensive treatment approach for attention-deficit/hyperactivity disorder (ADHD). The extended-release formulation is designed for once-daily administration, allowing healthcare providers to develop a treatment schedule based on the patient’s needs, response, and medical history. Current U.S. labeling lists 18mg as an available extended-release strength.
Each tablet contains 18mg of methylphenidate hydrochloride in an extended-release formulation. Methylphenidate is a CNS stimulant that affects activity in the brain and nervous system. Different manufacturers may use different inactive ingredients, so patients should always review the specific product labeling associated with their prescription.
Methylphenidate hydrochloride extended-release is a prescription medication and is classified as a Schedule II controlled substance in the United States. Because stimulant medicines can carry risks of misuse, abuse, and dependence, they should be taken only as prescribed and kept securely away from other people.
Sharing prescription stimulant medication is not appropriate, even when another person reports similar symptoms. A healthcare professional should determine whether methylphenidate is suitable and how the treatment should be monitored.
Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of ADHD in patients aged 6 to 65 years, according to current U.S. labeling. Medication may form one part of a broader ADHD treatment plan that can include behavioral, educational, and other supportive approaches.
The 18mg strength is listed as a recommended starting dose for children and adolescents who are new to methylphenidate. For adults who are new to methylphenidate, labeling lists 18mg or 36mg once daily as starting options. Individual dosing decisions should always come from the prescribing healthcare professional.
The 18mg extended-release tablet is intended for once-daily use, generally in the morning, with or without food. It should be swallowed whole with liquid. Patients should not chew, crush, or divide the tablet because doing so can affect its extended-release characteristics.
The prescribed dose should never be changed independently. If treatment response or side effects become a concern, the appropriate dosage adjustment should be discussed with a healthcare provider.
Before treatment begins, healthcare professionals may assess cardiovascular history and other factors that could affect stimulant safety. Patients should also discuss tics, Tourette’s syndrome, mental health symptoms, other medications, and any history of substance misuse with their provider.
For quality claims, wording such as “produced according to pharmaceutical quality standards” should only be included when it can be supported by documentation from the specific manufacturer. Avoid making unsupported manufacturing or quality claims on a product page.
